432
Views
7
CrossRef citations to date
0
Altmetric
Clinical Trial Evaluation

Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis

, &
Pages 1811-1813 | Received 23 Aug 2017, Accepted 17 Oct 2017, Published online: 14 Nov 2017
 

ABSTRACT

The recently published Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) assessed the efficacy and safety of abaloparatide (80 µg daily subcutaneous) (ABL) vs placebo during 18 months, in postmenopausal osteoporosis. Teriparatide (20 µg daily subcutaneous) (TPD) was used as an open label active comparator. The results of the study suggest that ABL increases bone mineral density more than TPD and reduces major osteoporotic fractures to a greater extent than TPD with a more rapid onset of action. These outcomes combined with a positive safety profile make ABL an interesting addition to the armamentarium against postmenopausal osteoporosis.

Declaration of interest

J.Y Reginster has received consultancy fees participated in paid advisory boards from IBSA-Genevrier, Mylan, Radius Health, Pierre Fabre; lecture fees when speaking at the invitation of the sponsor from IBSA-Genevrier, Mylan, CNIEL, Dairy Research Council (DRC); and grant support from industry via his institution from IBSA-Genevrier, Mylan, CNIEL, Radius Health. N.M Al Daghri has received support from the Prince Mutaib Chair for Biomarkers of osteoporosis, Deanship of Scientific Research Chairs, King Saud University, Riyadh, Saudi Arabia. O. Bruyere has received grant support or consulting fees from Bayer, Genevrier, IBSA, Meda, MSD, Nutraveris, Novartis, Pfizer, Rottapharm, Servier, SMB and TRB Chemedica. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

This paper did not received funding.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 884.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.